Literature DB >> 19053080

Identification and quantification of proteins differentially secreted by a pair of normal and malignant breast-cancer cell lines.

Xiquan Liang1, Jarkko Huuskonen, Mahbod Hajivandi, Raul Manzanedo, Paul Predki, Joseph R Amshey, R Marshall Pope.   

Abstract

Secreted proteins play a pivotal role in cellular functions. To better understand malignant behavior, we adapted stable isotopic labeling with amino acids in cell culture technology to identify and quantify proteins differentially released into the extracellular media by a pair of normal and malignant breast-cancer cell lines. Approximately 380 non-redundant proteins were quantified in serum-free media. Of the assigned proteins, 62% are classified secreted in protein databases and an additional 25% are designated secreted in the literature. A number of growth factors were found differentially regulated. Tumor necrosis factor, pigment epithelial-differentiating factor and stem-cell growth factor precursor showed decreased expression in breast-cancer cell line, whereas Inhibin beta and macrophage migration inhibitory factor show increased expression. Interestingly, protease inhibitors, including plasma protease (C1) inhibitor, PZP precursor, and SerpinE2 were significantly down-regulated in cancer cell line as were angiostatic factors from extracellular matrix (ECM) such as endorepillin. Further, the C-terminal fragment of type XVIII collagen, endostatin, a potent angiostatic factor, was down-regulated as well whereas extracellular collagens and osteoblast-specific factor 2 (OSF-2), were up-regulated. Differential expression and secretion of SerpinE2 and OSF-2 were confirmed using Western blotting. These results corroborate models of invasive tumors sustained by elaborate coordination of stromal cells via chemokines and growth factors, while protease inhibitors remodel the ECM to stimulate angiogenesis.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19053080     DOI: 10.1002/pmic.200700957

Source DB:  PubMed          Journal:  Proteomics        ISSN: 1615-9853            Impact factor:   3.984


  12 in total

Review 1.  Extracellular matrix composition reveals complex and dynamic stromal-epithelial interactions in the mammary gland.

Authors:  Ori Maller; Holly Martinson; Pepper Schedin
Journal:  J Mammary Gland Biol Neoplasia       Date:  2010-09-02       Impact factor: 2.673

2.  Characterization and detection of cellular and proteomic alterations in stable stathmin-overexpressing, taxol-resistant BT549 breast cancer cells using offgel IEF/PAGE difference gel electrophoresis.

Authors:  Manimalha Balasubramani; Chitose Nakao; Guy T Uechi; John Cardamone; Kathy Kamath; Kristen L Leslie; Raghavan Balachandran; Leslie Wilson; Billy W Day; Mary Ann Jordan
Journal:  Mutat Res       Date:  2010-09-09       Impact factor: 2.433

Review 3.  Cancer secretomics reveal pathophysiological pathways in cancer molecular oncology.

Authors:  George S Karagiannis; Maria P Pavlou; Eleftherios P Diamandis
Journal:  Mol Oncol       Date:  2010-09-16       Impact factor: 6.603

4.  Up-regulated proteins in the fluid bathing the tumour cell microenvironment as potential serological markers for early detection of cancer of the breast.

Authors:  Pavel Gromov; Irina Gromova; Jakob Bunkenborg; Teresa Cabezon; José M A Moreira; Vera Timmermans-Wielenga; Peter Roepstorff; Fritz Rank; Julio E Celis
Journal:  Mol Oncol       Date:  2009-11-23       Impact factor: 6.603

Review 5.  Sample preparation techniques for the untargeted LC-MS-based discovery of peptides in complex biological matrices.

Authors:  Inez Finoulst; Martijn Pinkse; William Van Dongen; Peter Verhaert
Journal:  J Biomed Biotechnol       Date:  2011-12-12

6.  Proteomic-based biosignatures in breast cancer classification and prediction of therapeutic response.

Authors:  Jianbo He; Stephen A Whelan; Ming Lu; Dejun Shen; Debra U Chung; Romaine E Saxton; Kym F Faull; Julian P Whitelegge; Helena R Chang
Journal:  Int J Proteomics       Date:  2011-10-24

7.  Deciphering the peptidome of urine from ovarian cancer patients and healthy controls.

Authors:  Christopher R Smith; Ihor Batruch; Josep Miquel Bauça; Hari Kosanam; Julia Ridley; Marcus Q Bernardini; Felix Leung; Eleftherios P Diamandis; Vathany Kulasingam
Journal:  Clin Proteomics       Date:  2014-06-02       Impact factor: 3.988

8.  Increased secretory leukocyte protease inhibitor (SLPI) production by highly metastatic mouse breast cancer cells.

Authors:  Kevin T Sayers; Alan D Brooks; Thomas J Sayers; Oleg Chertov
Journal:  PLoS One       Date:  2014-08-11       Impact factor: 3.240

9.  Variable stromal periductular expression of CD34 and smooth muscle actin (SMA) in intraductal carcinoma of the breast.

Authors:  Xavier Catteau; Philippe Simon; Michel Vanhaeverbeek; Jean-Christophe Noël
Journal:  PLoS One       Date:  2013-03-01       Impact factor: 3.240

10.  Myofibroblastic stromal reaction and lymph node status in invasive breast carcinoma: possible role of the TGF-β1/TGF-βR1 pathway.

Authors:  Xavier Catteau; Philippe Simon; Jean-Christophe Noël
Journal:  BMC Cancer       Date:  2014-07-09       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.